Priya Vakharia, MD
Ophthalmology · Palm Harbor, FLNPI 1215279500
Payments from drug & device makers
Across 1,331 payments — averaging $1822.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$1.4M
- Boehringer Ingelheim$567K
- Regeneron Healthcare Solutions, Inc.$143K
- Apellis Pharmaceuticals, Inc.$83K
- Genentech USA, Inc.$73K
- Astellas Pharma US Inc$68K
- plus $110K from 23 others
Across 6 payments — averaging $756.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3K
- F. Hoffmann-la Roche AG$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 675 | $1,380,623 |
| Boehringer Ingelheim | 11 | $567,258 |
| Regeneron Healthcare Solutions, Inc. | 171 | $142,804 |
| Apellis Pharmaceuticals, Inc. | 61 | $83,059 |
| Genentech USA, Inc. | 70 | $73,326 |
| Astellas Pharma US Inc | 54 | $68,102 |
| Bausch & Lomb Americas Inc. | 64 | $48,238 |
| AbbVie(2 entities) | 32 | $11,214 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $9,003 |
| ANI Pharmaceuticals, Inc. | 13 | $8,872 |
| Coherus Oncology, Inc. | 7 | $6,336 |
| Eyepoint US, Inc. | 9 | $5,238 |
| Boehringer Ingelheim International GmbH | 40 | $4,553 |
| Alimera Sciences, Inc. | 22 | $4,192 |
| Astellas Pharma Global Development | 5 | $3,730 |
| Ocular Therapeutix, Inc. | 9 | $3,568 |
| Notal Vision, Inc. | 45 | $1,548 |
| Genentech, Inc. | 2 | $1,499 |
| Alcon | 10 | $1,159 |
| Novartis | 4 | $269 |
| Harrow Eye, LLC | 5 | $129 |
| Amgen | 1 | $125 |
| Dompe US, Inc. | 1 | $122 |
| Stryker | 1 | $119 |
| Sun Pharmaceutical Industries Inc. | 1 | $116 |
| Dutch Ophthalmic, USA | 1 | $80 |
| Medtronic | 1 | $33 |
| Neurotech Pharmaceuticals, Inc. | 1 | $25 |
| Glaukos Corporation | 1 | $16 |
How this compares
$2,425,360 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other ophthalmology in Palm Harbor
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
- Benjamin ThomasJacksonville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.